Extended Data Fig. 3: Baseline demographics of patients who progressed prior to surgery in Arm 1 and patients who recurred within 14 weeks in Arm 2. | Nature Medicine

Extended Data Fig. 3: Baseline demographics of patients who progressed prior to surgery in Arm 1 and patients who recurred within 14 weeks in Arm 2.

From: Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

Extended Data Fig. 3

ECOG = Eastern Cooperative Oncology Group; HSV-1=herpes simplex virus 1; LDH = lactate dehydrogenase; T-VEC = talimogene laherparepvec; ULN = upper limit of normal.

Back to article page